Stocksigma LogoStocksigma Logo

Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization

Beta Drugs Limited confirmed nil deviation in utilizing funds from its ₹117.01 crore preferential issue (raised on 25th Nov'24) for the quarter ended 30th

Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization

Beta Drugs Ltd · Others (Uncategorized) · 22 Oct 2026, 11:07 pm

Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization Beta Drugs Limited confirmed nil deviation in utilizing funds from its ₹117.01 crore preferential issue (raised on 25th Nov'24) for the quarter ended 30th Sep'26. Against the allocated ₹117 crore, cumulative fund deployment reached ₹47.37 crore. Major deployments include ₹19.94 crore for capital investment/acquisitions (allocated ₹20 crore), ₹13.36 crore for general corporate purposes (allocated ₹15 crore), ₹9.52 crore for manufacturing capex (allocated ₹44 crore), and ₹3.60 crore for subsidiary facility upgrades. Brickwork Ratings India serves as the monitoring agency.

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements